TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...
The FDA approved Foundation Medicine’s cancer gene test Thursday. CMS also proposed national coverage of the test for Medicare beneficiaries with advanced cancer. The FoundationOne CDx is an in vitro ...
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...
Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...
(Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward ...
Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end. Ready ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results